生物制药企业因塞特医疗近日宣布，其研发的Jakafi XR™（鲁索替尼）缓释片剂已获得美国食品药品监督管理局（FDA）批准，将用于治疗骨髓纤维化、真性红细胞增多症以及移植物抗宿主病。此次获批标志着该药物在剂型上的重要升级，将为相关疾病患者提供更为便捷的每日一次服药选择。
生物制药企业因塞特医疗近日宣布，其研发的Jakafi XR™（鲁索替尼）缓释片剂已获得美国食品药品监督管理局（FDA）批准，将用于治疗骨髓纤维化、真性红细胞增多症以及移植物抗宿主病。此次获批标志着该药物在剂型上的重要升级，将为相关疾病患者提供更为便捷的每日一次服药选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.